A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Pfizer
Canadian Cancer Trials Group
Critical Outcome Technologies Inc.
Masonic Cancer Center, University of Minnesota
Amgen